As part of our strategy to expand globally and serve patients worldwide, filing the Certificate of Suitability (CEP) is a key milestone in our journey.

We are thrilled to announce that Alkem Activa has submitted the CEP application for 𝐐𝐮𝐞𝐭𝐢𝐚𝐩𝐢𝐧𝐞 𝐅𝐮𝐦𝐚𝐫𝐚𝐭𝐞 to the 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫𝐚𝐭𝐞 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐨𝐟 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 & 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 (𝐄𝐃𝐐𝐌).

This accomplishment reflects our unwavering commitment to advancing global healthcare. It also highlights Alkem Activa’s dedication to 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 and 𝐫𝐢𝐠𝐨𝐫𝐨𝐮𝐬 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐜𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞.

We remain committed to delivering excellence and supporting the needs of patients and healthcare providers across the globe.

Contact with us for your API requirements and let’s create success stories together.

To know more about our API’s visit to our website https://alkemactiva.com/contact or write to us at api@alkemactiva.com and we will be pleased to support your requirements.

One Brand, Countless health stories.